Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2012

01.02.2012 | Original Article

Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy

verfasst von: Norio Ieiri, Osamu Hotta, Toshinobu Sato, Yoshio Taguma

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Because of the well-established annual urinalysis screening system in Japan, the duration of nephropathy (DN) can be estimated in more than half of all patients with IgA nephropathy (IgAN). Treatment using a combination of tonsillectomy and steroid pulse (TSP) therapy has been reported as an effective method for obtaining clinical remission (CR), defined as negative hematuria and proteinuria, in IgAN patients. The present study aims to identify the correlation between DN and CR rate in IgAN patients treated by TSP therapy.

Methods

We retrospectively investigated 830 IgAN patients who were followed up for 81.6 months after TSP therapy. DN could be estimated in 495 of the 830 patients.

Results

The CR rate among patients with DN ≤36 months was 87.3% (295/338 patients). The CR rate among patients with DN of 37–84 months was 73.3% (63/86 patients), while that among patients with DN ≥85 months was 42.3% (30/71 patients). The CR rate among the remaining 335 patients in whom DN could not be estimated because of missing annual urinalysis results was 43.6% (146/335 patients). A multivariate Cox regression model using data from the former group of 495 patients showed that DN ≤36 months was a significant predictor of CR (hazard ratio 1.839; 95% confidence interval 1.410–2.398; P < 0.001).

Conclusion

Shorter DN is associated with higher likelihood of clinical remission in IgAN patients treated by TSP therapy.
Literatur
1.
Zurück zum Zitat D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64:49–60.PubMed D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64:49–60.PubMed
2.
Zurück zum Zitat Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–7.PubMed Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–7.PubMed
4.
Zurück zum Zitat D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.PubMedCrossRef D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.PubMedCrossRef
5.
Zurück zum Zitat Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18:1541–8.PubMedCrossRef Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18:1541–8.PubMedCrossRef
8.
Zurück zum Zitat Shu KH, Ho WL, Lu YS, Cheng CH, Wu MJ, Lian JD. Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Clin Nephrol. 1999;52:5–9.PubMed Shu KH, Ho WL, Lu YS, Cheng CH, Wu MJ, Lian JD. Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Clin Nephrol. 1999;52:5–9.PubMed
9.
Zurück zum Zitat Sezto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRef Sezto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRef
10.
Zurück zum Zitat Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.PubMedCrossRef Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.PubMedCrossRef
11.
Zurück zum Zitat Koyama A, Igarashi M, Kobayashi M. Members and Coworkers of the Research Group on progressive renal diseases. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef Koyama A, Igarashi M, Kobayashi M. Members and Coworkers of the Research Group on progressive renal diseases. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef
12.
Zurück zum Zitat Health and welfare statistics association. 2004 statistical abstracts on health and welfare in Japan. In: Statistical abstracts on health and welfare in Japan 2006. Health and welfare statistics association; 2006. Health and welfare statistics association. 2004 statistical abstracts on health and welfare in Japan. In: Statistical abstracts on health and welfare in Japan 2006. Health and welfare statistics association; 2006.
13.
Zurück zum Zitat Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef
14.
Zurück zum Zitat Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCrossRef Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCrossRef
15.
Zurück zum Zitat Suwa N, Takahashi T. Morphological and morphometrical analysis of circulation in hypertension and ischemic kidney. München-Berlin-Wien: Urban & Schwarzenberg; 1971. p. 108–116. Suwa N, Takahashi T. Morphological and morphometrical analysis of circulation in hypertension and ischemic kidney. München-Berlin-Wien: Urban & Schwarzenberg; 1971. p. 108–116.
16.
Zurück zum Zitat Ootaka T, Suzuki M, Sudo K, Sato H, Seino J, Saito T, et al. Histological localization of terminal complement complexes in renal diseases: an immunohistochemical study. Am J Clin Pathol. 1989;91:144–51.PubMed Ootaka T, Suzuki M, Sudo K, Sato H, Seino J, Saito T, et al. Histological localization of terminal complement complexes in renal diseases: an immunohistochemical study. Am J Clin Pathol. 1989;91:144–51.PubMed
17.
Zurück zum Zitat Hotta O, Taguma Y, Kurosawa K, Sudo K, Suzuki K, Horigome I. Predictive value of small crescents in IgA nephropathy: analysis of four patients showing a deteriorated renal function during a long follow-up period. Clin Nephrol. 1993;40:125–30.PubMed Hotta O, Taguma Y, Kurosawa K, Sudo K, Suzuki K, Horigome I. Predictive value of small crescents in IgA nephropathy: analysis of four patients showing a deteriorated renal function during a long follow-up period. Clin Nephrol. 1993;40:125–30.PubMed
18.
Zurück zum Zitat Sato Y, Hotta O, Taguma Y, Takasaka T, Nose M. IgA nephropathy with poorly development lymphoepithelial symbiosis of the palatine tonsils. Nephron. 1996;74:301–8.PubMedCrossRef Sato Y, Hotta O, Taguma Y, Takasaka T, Nose M. IgA nephropathy with poorly development lymphoepithelial symbiosis of the palatine tonsils. Nephron. 1996;74:301–8.PubMedCrossRef
19.
Zurück zum Zitat Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209–15.PubMedCrossRef Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209–15.PubMedCrossRef
20.
Zurück zum Zitat Hall CL, Bradley R, Kerr A, Attoti R, Peat D. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol. 2004;62:267–72.PubMed Hall CL, Bradley R, Kerr A, Attoti R, Peat D. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol. 2004;62:267–72.PubMed
21.
Zurück zum Zitat Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Seminars in Nephrol. 2004;24:244–55.CrossRef Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Seminars in Nephrol. 2004;24:244–55.CrossRef
22.
Zurück zum Zitat Droz D, Kramar A, Nawar T, Noël LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol. 1984;40:202–7.PubMed Droz D, Kramar A, Nawar T, Noël LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol. 1984;40:202–7.PubMed
23.
Zurück zum Zitat Nicholls KM, Fairley KF, Downling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984;53:227–50.PubMed Nicholls KM, Fairley KF, Downling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984;53:227–50.PubMed
24.
Zurück zum Zitat Beukhof JR, Kardaun O, Schaafsma W, Poortema K, Donker AJ, Hoedemaeker PJ, et al. Toward individual prognosis of IgA nephropathy. Kidney Int. 1986;29:549–56.PubMedCrossRef Beukhof JR, Kardaun O, Schaafsma W, Poortema K, Donker AJ, Hoedemaeker PJ, et al. Toward individual prognosis of IgA nephropathy. Kidney Int. 1986;29:549–56.PubMedCrossRef
25.
Zurück zum Zitat Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42.PubMedCrossRef Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42.PubMedCrossRef
26.
Zurück zum Zitat Frimat L, Briançon S, Hestin D, Aymard B, Renoult E, Cao Huu T, Kessler M. IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Néphrologues de l’Est. Nephrol Dial Transplant. 1997;12:2569–75.PubMedCrossRef Frimat L, Briançon S, Hestin D, Aymard B, Renoult E, Cao Huu T, Kessler M. IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Néphrologues de l’Est. Nephrol Dial Transplant. 1997;12:2569–75.PubMedCrossRef
27.
Zurück zum Zitat Kobayashi Y, Kokubo T, Horii A, Hiki Y, Tateno S. Prognostic prediction of long-term clinical courses in individual IgA nephropathy patients. Nephrology. 1997;3:35–40.CrossRef Kobayashi Y, Kokubo T, Horii A, Hiki Y, Tateno S. Prognostic prediction of long-term clinical courses in individual IgA nephropathy patients. Nephrology. 1997;3:35–40.CrossRef
28.
Zurück zum Zitat Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improved prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.PubMedCrossRef Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improved prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.PubMedCrossRef
29.
Zurück zum Zitat Radford MG, Donadio JV, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207.PubMed Radford MG, Donadio JV, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207.PubMed
30.
Zurück zum Zitat Donadio JV, Bergstralth EJ, Offord KP, Holley KE, Spencer DC. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clin Nephrol. 1994;41:65–71.PubMed Donadio JV, Bergstralth EJ, Offord KP, Holley KE, Spencer DC. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clin Nephrol. 1994;41:65–71.PubMed
31.
Zurück zum Zitat Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.PubMedCrossRef Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.PubMedCrossRef
32.
33.
Zurück zum Zitat Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.PubMedCrossRef Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.PubMedCrossRef
34.
Zurück zum Zitat Feriozzi S, Pierucci A, Roscia E, Cinotti GA, Pecci G. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens. 1989;7:S63–4. Feriozzi S, Pierucci A, Roscia E, Cinotti GA, Pecci G. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens. 1989;7:S63–4.
35.
Zurück zum Zitat Remuzzi A, Perticucci E, Ruggeneti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991;39:1247–73. Remuzzi A, Perticucci E, Ruggeneti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991;39:1247–73.
36.
Zurück zum Zitat Rekola S, Bergstrand A, Butch H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron. 1991;59:57–60.PubMedCrossRef Rekola S, Bergstrand A, Butch H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron. 1991;59:57–60.PubMedCrossRef
37.
Zurück zum Zitat Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9:265–9.PubMed Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9:265–9.PubMed
38.
Zurück zum Zitat Cattran D, Greenwood BS, Math M, Ritchie MD. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247–54.PubMed Cattran D, Greenwood BS, Math M, Ritchie MD. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247–54.PubMed
39.
Zurück zum Zitat Lewis EJ, Hunsicker L, Bain RP, Rhode RP, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.PubMedCrossRef Lewis EJ, Hunsicker L, Bain RP, Rhode RP, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.PubMedCrossRef
40.
Zurück zum Zitat The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.CrossRef The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.CrossRef
41.
42.
Zurück zum Zitat Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.PubMed Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.PubMed
43.
Zurück zum Zitat Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39:493–502.PubMedCrossRef Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39:493–502.PubMedCrossRef
Metadaten
Titel
Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy
verfasst von
Norio Ieiri
Osamu Hotta
Toshinobu Sato
Yoshio Taguma
Publikationsdatum
01.02.2012
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2012
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0530-1

Weitere Artikel der Ausgabe 1/2012

Clinical and Experimental Nephrology 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.